Drugs / Sodium Glycerophosphate
Sodium Glycerophosphate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | KABIVEN IN PLASTIC CONTAINER | — | 2014-08-25 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06842134 | Jan → May 2025 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04519762 Comparator | Sep → Dec 2020 | hypophosphatemia | Ain Shams University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Glycerophosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842134 ↗ |
| Known as | Glycophos | “Glycophos (Sodium Glycerophosphate)” NCT04519762 ↗ |
| Known as | SGP | “Organic phosphate (sodium glycerophosphate SGP)” NCT06842134 ↗ |
| Known as | Sodium glycerophosphate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067979 ↗ |
| Route | Intravenous | “Organic phosphate (SGP) will be diluted 1000mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 8.7 mmol over 9 h.” NCT06842134 ↗ |